KRW | Jotup

"LEQEMBI" Lecanemab) Approved for the Treatment of Alzheimer's Disease in South Korea

Retrieved on:

Mardi, mai 28, 2024

Patient, Ministry, KRW, Nursing, Diagnosis, MFDS, Alzheimer's disease, Neuron, Cell, Dementia, Eisai, Brain, MCI, Pharmaceutical industry

LEQEMBI is the first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline through this mechanism.

Key Points:

LEQEMBI is the first and only approved treatment shown to reduce the rate of disease progression and to slow cognitive and functional decline through this mechanism.
South Korea is the fourth country to grant approval, following approvals in the U.S., Japan, and China.
In South Korea, Eisai Korea Inc. will distribute the product and conduct information provision activities.
Eisai is committed to working together with healthcare professionals and other stakeholders to realize the early diagnosis and treatment of AD.

Kolmar BNH Expands Its Global Market by Launching HemoHIM G in Taiwan

Retrieved on:

Mardi, mai 28, 2024

Kolmar BNH (KRX: 200130), a prominent Korean health functional food Original Development Manufacturing (ODM) firm, announced that it has unveiled its latest offering, HemoHIM G, in Taiwan.

Key Points:

Kolmar BNH (KRX: 200130), a prominent Korean health functional food Original Development Manufacturing (ODM) firm, announced that it has unveiled its latest offering, HemoHIM G, in Taiwan.
View the full release here: https://www.businesswire.com/news/home/20240527924165/en/
Manufactured by Kolmar BNH and distributed by Atomy, HemoHIM G, containing Angelica sinensis, Ligusticum chuanxiong, and Paeonia lactiflora, is now available in Taiwan.
(Photo: Kolmar BNH)
HemoHIM G represents an enhanced iteration of HemoHIM, tailored to meet the distinctive tastes of consumers in Taiwan and Europe.
Kolmar BNH plans to expedite its market expansion in Asia by launching HemoHIM G in the Taiwan market on May 15.

K-Startup Grand Challenge 2024 revamped by KISED; South Korea invites 40 foreign startups

Retrieved on:

Jeudi, mai 16, 2024

View the full release here: https://www.businesswire.com/news/home/20240516794467/en/

Key Points:

View the full release here: https://www.businesswire.com/news/home/20240516794467/en/
KISED announced the start of applications for the 'K-Startup Grand Challenge 2024' program.
(Image: KISED)
K-Startup Grand Challenge (KSGC) is a global startup acceleration program financed by Korea’s Ministry of SMEs and Startups.
The program is designed to attract talented entrepreneurs and promising foreign startups to do business in Korea.
Accordingly, foreign startups participating in KSGC 2024 are expected to enjoy greater benefits in penetrating the Korean market.

KRAFTON Achieves Record-high Sales of 665.9 billion KRW in 1Q24

Retrieved on:

Mercredi, mai 15, 2024

KRAFTON recorded its 1Q24 sales of 665.9B South Korean Won, Operating Profit (OP) of 310.5B KRW, and Net Profit (NP) of 348.6B KRW following the Korean International Financial Reporting Standards (K-IFRS).

Key Points:

KRAFTON recorded its 1Q24 sales of 665.9B South Korean Won, Operating Profit (OP) of 310.5B KRW, and Net Profit (NP) of 348.6B KRW following the Korean International Financial Reporting Standards (K-IFRS).
Consolidated sales climbed 24.6% QoQ, setting a record-high quarterly sales.
Sales by business division are as follows: PC/Console 255.2B KRW, Mobile 402.3B KRW and Others 8.4B KRW.
Through various live services using PUBG: BATTLEGROUNDS IP, there has been high growth in all areas, including sales and traffic.

Kolmar BNH, a Top-Tier Korean Enterprise Specializing in the Production of HemoHIM, Dedicates over 2% of its Annual Sales to R&D

Retrieved on:

Vendredi, mai 10, 2024

Science, Research, Alternative Medicine, General Health, Health, Vitamins, Supplements, Fitness & Nutrition, Other Health, KRW, Workforce, Investment, ODM, BNH, KOSDAQ, Centrum, Fairy, Angelica sinensis, Multimedia

(Photo: Kolmar BNH)

Key Points:

(Photo: Kolmar BNH)
Founded in 2005, Kolmar BNH is an ODM company for health-functional food products.
ODM enterprises, encompassing various sectors from trend analysis to R&D, product conceptualization, manufacturing, and quality assurance, cater to customers with entrepreneurial aspirations.
The cornerstone of Kolmar BNH's competitiveness lies in its technological adeptness, underpinned by substantial R&D investments.
Kolmar BNH's stellar performance in sales among Korean health-functional food ODM firms can be attributed to the success of HemoHIM.

Korean Semiconductor Industry Titans Back DEEPX in Series C Funding Round

Retrieved on:

Vendredi, mai 10, 2024

AJU, AI, LLM, Robotics, Artificial intelligence, Growth, Communication, Silicon, VSD, Samsung Electronics, KRW, POSCO, EE Times, Investment

SEOUL, South Korea, May 9, 2024 /PRNewswire/ -- DEEPX , a prominent AI semiconductor technology startup under the leadership of CEO Lokwon Kim, is delighted to announce the successful conclusion of its Series C funding round, amassing $80.5M (KRW 110B).

Key Points:

SEOUL, South Korea, May 9, 2024 /PRNewswire/ -- DEEPX , a prominent AI semiconductor technology startup under the leadership of CEO Lokwon Kim, is delighted to announce the successful conclusion of its Series C funding round, amassing $80.5M (KRW 110B).
The round was spearheaded by SkyLake Equity Partners with participation from BNW Investments and AJU IB, alongside existing stakeholder TimeFolio Asset Management.
CEO Lokwon Kim expressed his admiration for Mr. Chin, stating, "Mr. DaeJe Chin, who elevated the Korean semiconductor industry to global prominence, is the ideal person to validate DEEPX's achievements.
DEEPX specializes in original on-device AI semiconductor and computing solutions across multiple sectors, including physical security, robotics, smart mobility, and artificial intelligence.

Gravity Reports First Quarter of 2024 Results and Business Update

Retrieved on:

Jeudi, mai 9, 2024

Online, Quarter, Ragnarök, Asset, International, Blockchain, Ragnarok Online, Federal Reserve Bank, Yoy, Gravity, International Financial Reporting Standards, Next Generation, Rebirth, KRW, Advertising, GGA, Gravity Interactive, Video game

Ragnarok Origin was launched in China on March 26, 2024 and North, Central, and South America in February 28, 2024.

Key Points:

Ragnarok Origin was launched in China on March 26, 2024 and North, Central, and South America in February 28, 2024.
And Gravity will publish the game in the rest of the global regions excluding Japan in the second half of 2024.
Gravity Communications Co., Ltd. is aiming to launch the first facility of Ragnarok Golf Monsters in Taipei, Taiwan in 2024.
The presentation contains the Company’s recent business updates, results of the first quarter in 2024 and Gravity’s business plan.

Gravity Announces Filing of Annual Report on Form 20-F for Fiscal Year 2023

Retrieved on:

Vendredi, avril 26, 2024

Security (finance), ADS, KRW, Bank statement, Annual report, Cryptocurrency

About GRAVITY Co., Ltd. ---------------------------------------------------Based in Korea, Gravity is a developer and publisher of online and mobile games. Gravity's principal product, Ragnarok Online, is a popular online game in many markets, including Japan and Taiwan, and is currently commercially offered in 91 markets. For more information about Gravity, please visit http://www.gravity.co.kr.

Key Points:

Seoul, South Korea, April 26, 2024 (GLOBE NEWSWIRE) -- GRAVITY Co., Ltd. (NasdaqGM: GRVY) (“Gravity” or the “Company”) today announced that the Company filed its annual report on Form 20-F for the fiscal year ended December 31, 2023 with the Securities and Exchange Commission on April 26, 2024.
The annual report can be accessed on the Company’s investor relations Web site at https://www.gravity.co.kr/en/ir/notice
The shareholders and ADS holders of Gravity may receive a hard copy of the annual report, which contains its audited consolidated financial statements, free of charge upon request.
Requests should be directed to IR Unit, Gravity Co., Ltd., 15F, 396 World Cup buk-ro, Mapo-gu, Seoul 03925, South Korea.
In the annual report on Form 20-F, the consolidated revenue is KRW 725,516 million, the operating profit is KRW 160,367 million, and the net profit attributable to parent company is KRW 132,019 million for the fiscal year ended December 31, 2023.

Hemohim, a Functional Food to Boost Immune System, Sparks Global Sensation

Retrieved on:

Lundi, avril 22, 2024

Food, Beverage, Vitamins, Supplements, Health, Retail, Fitness & Nutrition, Safety, Fairy, Research, Human, Herbal medicine, Fatigue, Ministry, Multimedia, KRW, KOSDAQ, Korea International Trade Association

Hemohim is garnering remarkable popularity in the global market as Korea's one of the leading functional foods.

Key Points:

Hemohim is garnering remarkable popularity in the global market as Korea's one of the leading functional foods.
Ranking the second-highest exported product after red ginseng in Korea, Hemohim is the leading individually approved health functional food ingredient.
After six years of endeavors, it obtained a fatigue recovery function last year, solidifying Hemohim's status as a dual-functional food with immune enhancement and fatigue recovery.
A Kolmar BNH official stated, "Hemohim represents Korea's top health functional food, backed by research capabilities and manufacturing prowess.

Samsung Biologics Reports First Quarter 2024 Financial Results

Retrieved on:

Mercredi, avril 24, 2024

Consolidated, KRX, CDMO, Samsung Biologics, KRW, ADC, Growth, Samsung

INCHEON, South Korea, April 24, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced financial results for the first quarter of fiscal year 2024.

Key Points:

INCHEON, South Korea, April 24, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced financial results for the first quarter of fiscal year 2024.
With accumulated orders exceeding USD 12.5 billion, the demand for our client-centric services remains robust," said John Rim, CEO and President of Samsung Biologics.
In the first quarter of 2024, Samsung Biologics reported a consolidated revenue of KRW 946.9 billion, marking a 31.3% increase from KRW 720.9 billion in the prior-year period.
On a standalone basis, Samsung Biologics reported KRW 669.5 billion in revenue,13.3% higher than the prior-year period, while operating profit reached KRW 232.7 billion.